Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very disturbing article! Stacking the trials by giving placebo to patients with pre-existing health issues, to the PR campaigns and false info tactics... big pharma was dirty and probably still is. FDA cannot be trusted either; after 3 vaxs approved for EAU they slammed the door on smaller competitors who actually had better efficacy and safety profiles because... Americans do not deserve better, safer drugs. At least that's the message I got from several recent articles. So I still believe big pharma needs to drop some coin, but ADMP, and get a safe and effective Tempol to the market fast.
We agree again! Thanks for the share!
Message in reply to:
MRK should be looking to acquire ADMP.
https://www.fool.com/investing/2021/10/06/merck-staring-down-patent-cliff-of-its-lucrative-c/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
That prior link is all the more timely given the concerns being raised (except by Mainstream media outlets!) about Merck's potential mutagenicity:
https://www.readcube.com/articles/10.1002%2Fem.2850190105
vs.
https://www.foxnews.com/health/merck-pill-oral-covid-treatment
Mainstream media will try to push this Merck product into the masses just like they did with vaccines, and it may be with equally tepid results. Remember when "science" originally said that as little at 40% vax rate would achieve herd immunity? If "science" was always right the first time, there would be no such thing as improvement of anything.
SRC, thank you for posting this link. I know you claim to share both sides but this is a refreshing show of support for our mutual investment. Please feel free to continue to do so!
Message in reply to:
MRK's pill, "serious health concerns"?
"Merck’s COVID-19 pill could carry serious safety concerns, scientists warn"
https://www.foxnews.com/health/merck-pill-oral-covid-treatment
The US has agreed to buy 1.7M courses of the Merck stuff for $1.2B! So that's over $700 per patient! That is awesome news for Adamis!
If Merck can get $700 for a 50/50 chance of helping a patient, then a 90%+ efficacy anticipated from Tempol should be worth waaaay more per patient, and if you ask anyone if they want a 50% chance of being cured or a 95% chance of being cured, I think we will see Adamis as a clear winner.
Couple that with ADMP's philosophy of NOT price gouging their customers, as shown by their offering of the least expensive epipens available, and we can see a future in which Adamis should absolutely dominate the COVID treatment market space.
To be more clear, Merck's update on their own drug is stated in very favorable terms. But a quick search immediately digs up the Wikipedia page, and the topic of Safety Controversy is right near the top:
"In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties. A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it."
If anything, this shows the desperation big pharma feels to get a COVID response drug to market regardless of possible patient safety issues. Do any of their drug candidates have a 30 year long safety profile? Nope. Only one that I know of, and that would be Tempol, doesn't yet qualify as a Big Pharma candidate.
Do I think a little player like Adamis has the political power and influence to get it approved and to market? Not without a struggle. Can Big Pharma push it through to an EUA once reasonable efficacy is shown? They sure could!
So the obvious answer here is that one of these desperate Big Pharma players needs to step in, buy Adamis outright, and get this ball rolling toward a Tempol EUA so the world has a safe and effective (and cheap to manufacture, BTW...) solution to get us through this pandemic with minimal loss of human life. And if we as Adamis stockholders should happen to profit tremendously from this life-saving business move, then I'll just have to deal with it.
Message in reply to:
Update on Merck's oral covid drug to show the competitive landscape that ADMP is facing. It's a 5 day oral treatment. Competition is heating up.
https://www.yahoo.com/finance/news/1-merck-says-research-shows-183245783.html
I dunno... I bought the bulk of my shares at sixty cents somewhere under a year ago. Up over 75% this year and looking to increase by ANOTHER 65% or so by using the daily "add a penny" trend that you pointed out for me! Thank you again for that!
I really wish all my "broken company" stocks were performing this poorly for me! At this rate (penny a day gain) my sixty cent shares will be worth over $1.70 on New Years Eve. Almost a triple! No lottery ticket at that point but a triple in about a year is still pretty respectable for ANY broken company, so I'm quite happy with this one.
Thanks again!
Monday, $1.03.
Tuesday, $1.04.
Wednesday. $1.05.
A penny a day puts ADMP higher than Titan's current PPS by the end of this year. That would be better than a 60% increase by then.
I appreciate it when people accidentally spread the good news about ADMP!
Welcome new investors! ADMP has a strong and relevant pipeline and product line! Awaiting financials to see just how effective our affordable Epi pens have been at penetrating the market, with a couple deals with big retailers helping out. Upcoming products will help deal with the nation's addiction crisis by saving many of those lives, and our COVID fighter Tempol should be a viable for EUA long before trials are completed. Add in announcements for the sale of our compounding facility and funding for trials, and we have a winner on our hands.
Investing in ADMP or any other company is about the future, and ADMP's future looks extremely bright - hopefully bright enough to make them an imminent acquisition target. And with the fictitious negativity available publicly, this is currently a massive bargain!
Data from the sources... read it for yourself. Don't be misinformed by unofficial reports from any other place. Get real info. Here are the links to the latest.
https://clinicaltrials.gov/ct2/show/NCT04729595?term=tempol&draw=2&rank=1
https://earlycovidstudy.com/find-a-study-clinic/
Frankestin, did you watch the presentation? If so, what are your thoughts? I wasn't able to log in.
ORNurse, I would have agreed with that 8 or 10 years ago. But I think there is a market dependency as well. Trixie (Asenseless) has proven that it takes more than money to let a little guy into this market. ISRG is now so entrenched that it will take a big fish to take a sizeable bite out of this market. And Titan's PPS is so low (for what it has developed) that dilution absolutely would kill the longs. At this point I am only in it for acquisition.
Some folks may not realize it but Medtronic has acquired numerous companies in the past. Upon acquisition, most of the target companies' employees become employees of Medtronic, although many didn't even get a name change on the building they worked at. At most the sign might now read Mazor Robotics, and in small print below that it might say "A wholly owned subsidiary of Medtronic plc". A strategic acquisition is for an entire company like Titan, not just the results of their work up to a point. Buying a company is for the future, and the expertise to optimize Enos and subsequent related technologies resides within the Titan engineering team. As an acknowledgement of that expertise, the giant whale of a company Medtronic said something like "Crap, these guys at Titan are doing a better job than we are at developing surgical robotics so maybe we need to get our hands on that expertise." Milestones are proof that they will get the expertise they need for tasks they obviously couldn't manage successfully themselves.
Is Hugo really any better than Trixie's Senhance? Or does it have a chance at success becaue they have the marketing power of Medtronic pushing it into the market? I'm guessing the latter, almost entirely. They know their product isn't a revolution in robotic surgery, but that's what they will need to go head to head with ISRG or to make a worthwhile profit in that market. "Help us Obi Wan McNally, you're our only hope!"
Conferences are business as usual for Titan. That is surely their directive. I'm pretty sure Mr. Martha did not tell Mr. McNally to do things which arouse shareholder suspicion regarding potential acquisition. I would think it would be fairly obvious to some people if they completely stopped all conferences, so they have to continue on as if nothing different is coming. Besides, the deal isn't done until it is done.
More profitable? Possibly - or maybe not. But an equity stake would foretell their intentions, as it did with Mazor. Medtronic did not like the outcome with the Mazor deal for a couple reasons. First, share price shot up too much and some folks bought Mazor shares in the mid to upper $70's when buyout was in the $50's. PPS overshot the goal, which certainly wasn't MDT's intention. Second, Geoff Martha recently noted that they had issues with the Mazor product line which needed to be resolved after acquisition. He hinted that their preference moving forward would be to acquire pre-market growth and then grow it organically under Medtronic; this appears to be backed by his public disparagement of the Mazor product.
I guess it was more profitable in the Mazor scenario for people who SOLD their shares at $78 but those buyers got screwed, and the sellers seemed to be in the minority. I don't think Mr. Martha wants it to play out like that again.
Therefore, I am not "predicting" acquisition at any particular time such as in the next 4 to 6 weeks, but I am saying that I personally believe it would be the RIGHT thing for Medtronic to do, based on the two reasons stated above and the reasons I put forth in my prior post.
Message in reply to:
As always thank you for your insightful posts. However, don’t you think that an equity stake by Medtronic into Titan (similar to the Mazor/Medtronic deal) would be more prosperous for shareholders than a straight buyout after Milestone 4?
Medtronic could well have been planning to complete acquisition upon completion of Milestone 4, which remains a very viable theory given Mr. McNally's prior statement that the future of Titan Medical will be very obvious when Milestone 4 is completed. That being said, it would mean Medtronic was planning the acquisition for September or immediately thereafter, as we know that was the initial due date for Milestone 4 and earlier this year we were told it is still on schedule for September.
Milestone 4 is for delivery of a functional prototype of... something... which requires "custom metal" parts from Europe, the delivery of which has been reported to be delayed due to COVID, but is anticipated to allow completion of Milestone 4 by the end of this year. Delivery of a prototype or even a few prototypes out of Chapel Hill would not typically require anything custom made in Europe; the added risk of shipping alone (including Customs) would logically rule out that option. So there must be a reason for that vendor to have been selected, such as maybe that vendor is already a favored supplier for other Medtronic parts and they don't want the hassle of introducing another supplier to their supply chain, including checking certs and validating capabilities and all the other BS required for a medical device manufacturer to bring on a new supplier. So my hypothesis remains that the vendor in question is a Medtronic supplier and Titan was told to use them for said parts.
So if Medtronic told Titan to use said supplier, and the delay is because of this choice of supplier, would it be fair to Titan and their dedicated shareholders to delay acquisition merely because your tier 2 supplier had COVID issues when trying to fulfill Titan's purchase order? If everything else was potentially being lined up for a September or early October acquisition, why would they want to kill that momentum? At this juncture I'm quite sure Mr. Martha knows exactly what is being designed, built, and delivered for fulfillment of the Milestone.
Meanwhile, patents are being approved at an astronomical rate (by patent office standards) and each of those should be driving Titan's real value and therefore acquisition price up substantially. There is therefore a sound logical argument to acquire as per the original plans, and a moral requirement to not impose a delay in acquisition merely because Medtronic wanted to save themselves some legwork when eventually putting this prototype hardware into production.
Next catalyst? I don't know for sure, but I have just outlined what I'm hoping for... Acquisition would be the ultimate catalyst!
Message in reply to:
What’s everyone’s guess for the next catalyst? I’m getting bored.
These two links will provide updates to anyone interested in how the trials are going along. And any legitimate investor wants to know how the trials are going.
This post should be Stickied for easy reference for ADMP shareholders.
https://clinicaltrials.gov/ct2/show/NCT04729595?term=tempol&draw=2&rank=1
https://earlycovidstudy.com/
Only Claim 1 was canceled, the rest of the patent was pursued and granted. This has happened in the past as well.
Endoluminal Natural Orifice Surgery
Message in reply to:
…or perhaps Endoscopic Natural Orifice Surgery?
Big news indeed will be coming!
hey will Roll through the Tempol trials for COVID where safety and efficacy are both already known (safety with decades of other uses and efficacy from limited data to date but about to be strongly reinforced by the new trials)and maybe seek EUA or maybe market in other countries where regulatory is more straight forward.
A couple people decided to Roll themselves into prison by pleading guilty in the doping scandal, which should close that case and free up our financial reports for the past couple quarters, and our sales stats on Epi Pens alone should be a nice driver for PPS to Roll upwards.
Then when the FDA decides to Roll out their decision on Zimhi, we Roll in high gear!
Message in reply to:
Soon ADMP will Roll out some big news and it will be duck and cover baby!
Next year lots of folks should be happy to!
Message in reply to:
Can someone fill my $10 sell orders?
For clarification, the links to view the sites show 6 sites; one is already open and enrolling patients, and the other 5 (all are around the Southeastern US) will be opening soon! Scroll down for the links.
Anyone here who is geographically near those sites and knows someone very recently diagnosed with Covid should send this link along with a recommendation, and a reminder that the drug has decades of use (for other indications) to show safety. It would be extremely cool to have some ADMP investors here being able to provide direct testimony on Tempol results for friends or family members.
Message in reply to:
New site and Tempol/ADMP Sites.....Nice......Read....
https://earlycovidstudy.com/
That is a great link for us! Nice to see Tempol so prominently displayed on ANY web site!
Message in reply to:
New site and Tempol/ADMP Sites.....Nice......Read....
https://earlycovidstudy.com/
Thanks Roll.....better than discussing March calls.Wheeeeewwww!!!
My biggest ADMP buy was at 60 cents. Yup, not even doubled yet. Must be broken, I'd say!
Not worth arguing with someone who thinks 30 (reverse split ratio) times $.03 equals $1.55.
Great News!!
ADMP Trial underway at 8:15am per Clinical site...
The stress is finally over for the commencement of the Trial. Now we wait for official PR from IR this am...
Next?? Funding granted?? Zimhi?? Interim Analysis?? Exciting times ahead for us.
https://clinicaltrials.gov/ct2/show/NCT04729595?term=tempol&draw=2&rank=1
Nice post and great synopsis of everything Adamis shareholders have to look forward to!
Anyone feel like digging into other recent patents to see how many of them were Colorado-based inventors? I bet there's a few.
Over a million pre-market volume already. Could be a good day. Could be.
For those folks who believe giving away half the profits while bearing NO expense is a bad business model, I offer this indication from our covid competitor Pfizer who is dumping over $17B for a similar arrangement:
https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/
Nobody seems to be beating them up for this arrangement.
So they don’t want to split profits on the next covid med, not actually so much the point... but re-read the prior link and compare to Tempol results and we can all wonder why we aren't fast tracked to our EAU. Big Pharma rules for now, but the little guys will get our come uppance in due time.
https://clinicaltrials.gov/ct2/show/NCT04960202
Always good to know what the competition is doing and why we are so much better! A little digging goes a long way.
Nice! Now if only the NIH would mention Adamis by name!
I feel like Dennis in The Holy Grail...
"Help! I'm being repressed! (Can't you see the violence inherent in the system???)"
Message in reply to:
Yes sir! LFG!!!
Link:
https://flashalert.me/?symbol=ADMP&source=PR&referer=https://stocktwits.com/&url=https://www.globenewswire.com/news-release/2021/08/19/2283482/32832/en/Adamis-Highlights-National-Institutes-of-Health-NIH-Article-Entitled-Tempol-A-Potential-Home-Treatment-for-COVID-19.html&s3=ADMP/2021-08-19/07-33-23_000000/glob/e997061632b5f5f751a09cf1edfb8d06/Adamis-Highlights-National-Institutes-of-Health-NIH-Article-Entitled-Tempol-A-Potential-Home-Treatment-for-COVID-19.html
BK, don't forget that the delay isn't so much on Titan as it is on the supplier for these "custom metal" parts from Europe which are delayed due to covid, according to Mr. McNally. And since these parts are for the Milestone 4 prototype hardware, chances are that Medtronic specified who the supplier should be, given that A. they are in Europe, and B. they should be positioning themselves with suppliers who can support the program once in production. So it was PROBABLY MDT's selection of supplier which is causing the delay, so naturally they will be quite forgiving about a "delay".
Message in reply to:
Why so much gloom.....
It's terrible that the 4th milestone was delayed, but as I've said before there's a completely logical possibility.
The 4th milestone completion is the key to unlock the question(s) as to what's next with TMDI.
THE LOAN. With the most ridiculous provisions for a minuscule $1M amount, to pay off a consultant suit, and put all of the company IP as collateral. If that's not the biggest, most obvious LOOK HERE b/c this is what we're doing and can't tell you about it. I don't know what else they could have done with the gag-clause in place.
If the 4th milestone were to be executed on time, and no new amendments or addendums to the develop agreement - then the loan could be paid in full. Then TMDI is free to do business with anyone of their choosing.
This would put MDT at great risk, of sharing the IP that which they have licensed. Which at the time of the announcement was 10-14 patents? Martha hates that - his words. He's the new CEO b/c he was the former head of MDT Acquisitions. Or worse, another RAS med-tech company jumps in front of MDT. Don't think MDT will permit that so they said, "hey, tweak this" before we consider the 4th milestone completed. "It's ok if it takes a few months longer." What I think it means is "we don't want you to have the option of paying off the loan at this time." "Keep working on the 4th milestone."
Hard to know the real truth, but in spite of all the negativity and faux bashing of the condition of the company, NO ONE can deny the company is in the best shape financially and down the path of progress on ENOS.
Better than at any other time.
I will feel no sorrow for anyone selling between now and next summer. B/c no one knows what will happen tomorrow, next week, or next month. Once you sell, you will need to sit for 30 days for the wash sale rules..... Somehow that point always seems to be missing in the sell now and buy back later messages.
Good luck to all. Regards,BK.
I tried to tie it back to the possibility of someone, maybe big pharma, exerting influence to suppress the connection between Tempol and Adamis in order to prevent spikes in PPS which could give Carlos a stronger negotiating position in a potential acquisition situation. I consider the mere mention of potential acquisition to be a positive (for both of my two favorite stocks).
Without some possible justification as to WHY they seem to remain anonymous while Tempol is getting some great press, it would seem to only be negative. That CNBC article could have bumped us up substantially if they had mentioned the company, but nooo... their identity remains suppressed. And if there is no legitimate, viable reason for the company to fly so far under the radar screen while moving forward with a groundbreaking, life-saving treatment for the most severe pandemic in modern history, well then I guess that would be a negative. I consider that to be intuitively obvious so I try not to harp on it too much, and instead point out the less obvious possible explanation which would be absolutely, wonderfully positive if it (acquisition) turned out to be the correct answer.
Message in reply to:
Back on 6/3/21 I mentioned this lack of connection between Tempol and ADMP in my post 2628 and was told I was being negative. Fast forward over 2 months, I agree with you on this point.
ShortsRClowns Thursday, 06/03/21 05:12:29 PM
Re: OR Nurse post# 2626 0
Post # of 3109
Is it me or was ADMP NOT MENTIONED by name in the article at all? Huge missed opportunity in some ways if I'm not mistaken about them not being mentioned by name. It was a right front page story on CNBC, still is.
WTF!
Today is a terrible day. Other covid pharma companies have their names tied to announcements about their meds, like VRPX going from $4.XX Monday to a pre-market high of $37 today on one stupid announcement which says they are in the works but far behind Tempol's progress. Meanwhile, Tempol is marching forward with the NIH study, and every time NIH says Tempol they should also say Adamis, yet the company is never mentioned and the share price lounges near the $1.00 mark eternally and depressingly. One little article bumps the competition up 500 to 1000% in 2 days but our legitimate progress doesn't get credited to the company and so maybe we accidentally pick up a few % on the day, big whoop... we should be seeing the kind of gains that the competition gets for substantially more insignificant announcements.
Why? Is the NIH instructed to avoid mention of the Adamis name so our PPS doesn't shoot up like the competition? Are we being manipulated in preparation for acquisition? Who knows. But meanwhile, it makes for another terrible day while others get the glory our little company rightfully deserves.
That's odd... the NASDAQ site is saying $1.61 for TMDI. I know, that info is probably Off Topic when I write it.
Message in reply to:
1.50
Per the IR Presentation on the Titan Medical web site, they had 82 patents approved and 95 Pending as of June 30, 2021. Looking at Frankestin's posts since then and disregarding the one patent which called out Titan but it wasn't their patent...
July 6, 1 approval
July 29, 3 approvals
August 5, 2 approvals
Today, 1 more. That's 7 more approvals for Titan since the 82 approved as of June 30, so we are at 89 approved patents, with at least 88 more pending. Who knows how many more applications they have submitted since then, but between the Enos rapid development program and the joint Titan/MDT development program, there may have been several more recent apps. I suspect Mr. Brar is very busy these days... generating huge eventual value for shareholders!
Message in reply to:
Wow!! Thanks Frankenstein
Titan Medical now holds 83 issued patents and 94 patent applications. That is quite some portfolio in an up and coming market that might be worth a lot of $$$
Why would I want to debate Bill Gates? Because he was looking at ludicrous places to ditch some of his wealth before the divorce wraps up? You are making no sense here. Bill Gates has nothing to do with Titan.
I agree that Silly would be helping your competition to take away your own future market share. Totally illogical. Senseless. Even the folks who seem to distrust or dislike Mr. McNally would agree that is a bad idea. And I also believe Mr. McNally himself would believe it is a bad idea. That is also why I believe he isn't doing that. And the only way for him to not be doing something this senseless would be if he knows that the end result is in this case an acquisition.
As for Aspire... I submitted the question this morning regarding Aspire but Kristen cut out the part about rationale for doing it so soon instead of waiting until PPS rises from some good milestone announcements to limit the dilution. All we got was "to extend the runway..." which is already over a year long. At least you and I agree dilution is bad.
Message in reply to:
Yeah - I'd like for you to debate Mr. Bill Gates - Titan is not a secret (10 years and counting)...now HUGO is doing GYN procedures, Silly is actually helping a competitor take away their own future market share and for what....$41M freakin bucks? That right there should tell ya all ya need to know. How many more feebies does Aspire get to buy the remaining 2.7M they are obligated too (by contract) ?? Enough is enough
** Oh - and she is now RED BTW at $1.65
Some fairly simple math here...
$55M in cash. Just over 5 quarters left to end of 2022. Burn rate of $10.9M/quarter. Times 5 quarters, that would be $54.5M. And someone thinks this is bogus? $10.9M per quarter is a surprise? Or is it simple math, but by pretending it is extravagant, one spins a negative connotation onto what is really good news.
Let's compare that to Vickie (Vicarious). $1.1B in funding. That's more than a 1000 quarter budget, or 250 years of funding at Titan's burn rate. So... Is Vickie gonna take 250 years to get to market? Or is Titan's burn rate actually extremely conservative (and therefore IMPRESSIVE!) for the task at hand, when compared to the so-called "competition"? And what does Vickie have to show for their extravagant budget? 4 patents and a handful of lawsuits. What does Titan have for their relatively meager spend rate? A fully functional robotic surgery system, touted by one of the most experienced robotic surgeons on the planet.
See how simple math REALLY works when one has the right frame of mind and isn't trying to sabotage their investment?
Should that not be 89 patents issued and 88 or more pending?
The quarterly report said 82 issued and 95 pending as of June 30; I assume your tally adds in the approvals since then (7 more approved?) to bring you to 89 approved; that would leave 88 unless they have applied for more since then - which appears likely given the pace of their development lately.
Message in reply to:
shorts await accounts!
I'm waiting for progress!
89 US and international patents issued
77 (or more) Applications Pending